Last reviewed · How we verify
Mitomycin for Injection
Mitomycin is an antibiotic that alkylates DNA, creating cross-links that prevent DNA replication and transcription, leading to cell death.
Mitomycin is an antibiotic that alkylates DNA, creating cross-links that prevent DNA replication and transcription, leading to cell death. Used for Gastric cancer, Colorectal cancer, Bladder cancer.
At a glance
| Generic name | Mitomycin for Injection |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Antibiotic alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mitomycin is a naturally derived antibiotic that functions as a DNA-alkylating agent. After metabolic activation, it covalently binds to DNA and forms interstrand cross-links, which block DNA synthesis and repair mechanisms. This results in apoptosis and cell death, making it effective against rapidly dividing cancer cells.
Approved indications
- Gastric cancer
- Colorectal cancer
- Bladder cancer
- Breast cancer
Common side effects
- Myelosuppression (leukopenia, thrombocytopenia)
- Nausea and vomiting
- Hemolytic uremic syndrome
- Pulmonary toxicity
- Nephrotoxicity
Key clinical trials
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (PHASE3)
- Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma (NA)
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (PHASE1, PHASE2)
- Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids (PHASE2)
- Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery (PHASE3)
- Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture (PHASE2, PHASE3)
- Precise Neoadjuvant Chemoresection of Low Grade NMIBC (PHASE2)
- Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |